| Literature DB >> 28534862 |
Signe M Nielsen1,2, Rikke L Meyer3, Niels Nørskov-Lauritsen4.
Abstract
Bacteria of genus Achromobacter are emerging pathogens in cystic fibrosis (CF) capable of biofilm formation and development of antimicrobial resistance. Evolutionary adaptions in the transition from primary to chronic infection were assessed by transcriptomic analysis of successive isolates of Achromobacter xylosoxidans from a single CF patient. Several efflux pump systems targeting antimicrobial agents were upregulated during the course of the disease, whereas all genes related to motility were downregulated. Genes annotated to subsystems of sulfur metabolism, protein metabolism and potassium metabolism exhibited the strongest upregulation. K+ channel genes were hyperexpressed, and a putative sulfite oxidase was more than 1500 times upregulated. The transcriptome patterns indicated a pivotal role of sulfur metabolism and electrical signalling in Achromobacter biofilms during late stage CF lung disease.Entities:
Keywords: adaptation; antimicrobial resistance; cystic fibrosis; efflux pumps; sulfur metabolism; transcriptomics
Year: 2017 PMID: 28534862 PMCID: PMC5488654 DOI: 10.3390/pathogens6020020
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Antimicrobial susceptibility of successive Achromobacter xylosoxidans isolates.
| Antibiotic (µg/mL) | CF2-a (Early) | CF2-b (Intermediate) | CF2-d (Late) | |||
|---|---|---|---|---|---|---|
| MIC | Categorisation * | MIC | Categorisation * | MIC | Categorisation * | |
| Amikacin | >32 | R | >32 | R | >32 | R |
| Aztreonam | >16 | R | >16 | R | >16 | R |
| Cefepime | 16 | R | 8 | S | >16 | R |
| Cefotaxime | 32 | NI | >32 | NI | >32 | NI |
| Ceftazidime | 4 | S | 4 | S | 8 | S |
| Ciprofloxacin | 2 | R | 2 | R | >2 | R |
| Colistin | 1 | S | 1 | S | > 8 | R |
| Doripenem | 0.25 | S | 0.25 | S | 2 | I |
| Doxycycline | 8 | NI | 8 | NI | 8 | NI |
| Ertapenem | ≤0.25 | NI | 1 | NI | >4 | NI |
| Gentamicin | >8 | R | >8 | R | >8 | R |
| Imipenem | ≤1 | S | 2 | S | ≤1 | S |
| Levofloxacin | 2 | R | 2 | R | > 8 | R |
| Meropenem | ≤1 | S | ≤1 | S | 4 | I |
| Minocycline | ≤2 | NI | ≤2 | NI | 4 | NI |
| Piperacillin | 8 | S | 8 | S | 8 | S |
| Polymyxin B | 1 | NI | 1 | NI | 4 | NI |
| Ticarcillin/Clavulanic Acid | ≤16 | S | ≤16 | S | ≤16 | S |
| Tigecycline | ≤0.25 | NI | 0.5 | NI | 0.5 | NI |
| Tobramycin | > 8 | R | > 8 | R | > 8 | R |
| Trimethoprim/ Sulfamethoxazole | ≤0.5 | NI | ≤0.5 | NI | ≤0.5 | NI |
* Interpreted according to EUCAST susceptibility breakpoints for Pseudomonas species; S: Sensitive; I: Intermediate resistance; R: Resistant; NI: No Interpretation; MIC: minimal inhibitory concentration.
Differentially expressed genes in early and late isolates of A. xylosoxidans.
| Gene Function | Downregulated Genes in the Late Isolate | Upregulated Genes in the Late Isolate | Fold Change * |
|---|---|---|---|
| Arsenic resistance | 1 | 8.2 | |
| Zinc resistance | 2 | 14.1 to 20.5 | |
| Type III secretion system | 10 | −29.0 to −7.8 | |
| Flagellar motility | 3 | −11.3 to −5.4 | |
| Beta-lactamase | 1 | 23.3 | |
| Multidrug resistance efflux pumps | 4 | 6.1 to 23.5 | |
| Capsular and extracellular polysaccharides | 2 | 2 | −9.4 to 5.2 |
| Lipopolysaccharide assembly | 1 | 8.8 | |
| Bacterial peptidoglycan hydrolases | 1 | 9.2 | |
| EPS biosynthesis | 1 | 5.9 | |
| Capsular polysaccharide ABC transporter | 1 | 6.6 | |
| Anaerobic respiratory reductases | 2 | 6.1 to 9.0 | |
| Formate dehydrogenase | 2 | 5.3 to 6.7 | |
| Soluble cytochromes | 1 | 9.6 | |
| Fermentation | 1 | 7.3 | |
| Nitrogen Metabolism | 1 | 7.2 | |
| Dentrification | 1 | 46.0 | |
| Cytochrome O ubiquinol oxidase subunit I–IV | 4 | −20.7 to −7.3 | |
| Succinate dehydrogenase | 1 | −9.4 | |
| Cold shock | 2 | 5.5 to 10.7 | |
| Detoxification | 1 | 10.4 | |
| Osmotic stress | 3 | 5.1 to 8.6 | |
| Oxidative stress | 2 | 9.5 to 11.8 | |
| Heat shock | 1 | −5.4 | |
| DNA recombination | 2 | −6.5 to −5.9 | |
| DNA repair | 1 | −6.7 | |
| Inorganic sulfur assimilation | 4 | 10.1 | |
| Organic sulfur assimilation | 1 | 6 | −5.7 to 22.7 |
| Sulfur metabolism | 2 | 313.8; 1516.2 | |
| Protein degradation | 3 | 7.9 to 24.7 | |
| Protein biosynthesis | 1 | 6.3 | |
| Protein processing and modification | 2 | 201.2 to 756.1 | |
| Osmosensitive K+ channel histidine kinase | 4 | 8.7 to 128.0 |
* Late isolate compared with early isolate.
Figure 1Gene expression in genes involved in protein, sulfur and potassium metabolism in early, intermediate and late isolate. Darker colour corresponds to higher gene expression, ranging from 16 to 38,628 reads, normalized to reads per kilobase per million mapped reads (RPKM), averaged from three replicates. Exact gene expression values are shown in Table S1. * Gene function according to Rapid Annotation using Subsystem Technology (RAST) annotation.
Minimal biofilm eradication concentration (MBEC) of selected antimicrobials with and without addition of efflux pump inhibitor PaβN.
| Antibiotic (µg/mL) | CF2-a (Early) | CF2-b (Intermediate) | CF2-d (Late) | |||
|---|---|---|---|---|---|---|
| MIC | MBEC | MIC | MBEC | MIC | MBEC | |
| Colistin | 1 | 128 | 1 | 128 | >8 | 2048 |
| +PAβN (100 µg/mL) | 1 | ≤32 | 1 | 64 | >8 | 2048 |
| Levofloxacin | 2 | 128 | 2 | 128 | >8 | 256 |
| +PAβN (100 µg/mL) | 2 | 128 | 2 | 128 | 4 | 256 |
| Tobramycin | >8 | 512 | >8 | >1024 | >8 | >1024 |
| +PAβN (100 µg/mL) | >8 | 512 | >8 | >1024 | >8 | >1024 |
| Piperacillin | 8 | 2048 | 8 | 2048 | 8 | >2048 |
| +PAβN (100 µg/mL) | 8 | 2048 | 8 | 2048 | 8 | >2048 |